“Translating discovery into decisive clinical impact.”
Pavan Battiprolu stands at the intersection of medicine, science, and enterprise value creation—a clinician-scientist and biopharmaceutical executive whose career has been defined by his ability to transform scientific insight into therapeutic reality. With more than two decades of leadership spanning discovery, translational research, and clinical development, he has built and scaled precision-driven development engines across genetic medicines, immunology, cardiometabolic disease, and advanced therapeutic modalities. From operating rooms in India to boardrooms guiding IPO-stage biotech strategy, Pavan’s journey reflects a rare fusion of clinical intuition, scientific rigor, and strategic foresight.
His professional foundation was forged in the operating theaters of Madras Medical Mission & Care in India, where he assisted in more than 200 congenital and adult cardiac surgeries. As a Surgical Physician Associate specializing in cardiothoracic care, he developed firsthand insight into the urgent unmet needs of patients with life-threatening conditions. During this formative period, he helped establish one of India’s early valve banks and conducted biomarker research in cardiac ischemia, presenting findings at national cardiothoracic forums. These early clinical experiences instilled in him a lifelong commitment to improving patient outcomes through scientific innovation.
Driven to understand disease at its mechanistic roots, Pavan pursued a Ph.D. in Metabolic Disorders at Idaho State University, where he conducted NIH-funded research exploring sex-specific cardiac metabolism and novel therapeutic targets in muscle physiology. His work identified new metabolic pathways with translational potential, laying the groundwork for his enduring focus on cardiometabolic disease. He continued his scientific ascent as a Distinguished Postdoctoral Fellow at UT Southwestern Medical Center, supported by prestigious fellowships from the American Heart Association and American Diabetes Association. There, he developed pioneering models of diabetic cardiomyopathy and elucidated the role of autophagy in cardiac function—research that would shape his global reputation in metabolic biology.
Pavan transitioned to industry with Amgen in South San Francisco, where he served as Senior Scientist and Translational Lead for Cardiometabolic Disorders. At Amgen, he played a critical role in advancing assets such as Repatha (evolocumab), contributing to biomarker strategy, target discovery, and in-licensing initiatives. His leadership extended to managing high-value strategic alliances, including collaborations with Cytokinetics, and guiding portfolio decisions that balanced scientific opportunity with commercial viability. His discovery publications during this period established mechanistic links between novel targets and disease outcomes, reinforcing his ability to bridge bench science and clinical application.
In 2017, Pavan joined Rocket Pharmaceuticals as one of its earliest team members, becoming a founding force in the company’s transformation from startup to publicly traded enterprise. Wearing multiple leadership hats, he designed end-to-end translational frameworks for AAV gene therapy programs and drove multiple IND submissions within a single year across metabolic and cardiac portfolios. He was instrumental in lifting an FDA clinical hold for the Danon disease program and securing key regulatory designations such as Orphan Drug and RMAT status. His translational validation work played a central role in investor confidence and funding rounds, while his co-authorship of a landmark New England Journal of Medicine publication demonstrated clinical proof-of-concept in gene therapy.
Building on this momentum, Pavan assumed leadership roles at Poseida Therapeutics as Executive Director and Head of Translational Medicine for Gene Therapy. There, he established non-viral gene therapy translational platforms targeting Hemophilia A, Hereditary Angioedema, and rare liver and metabolic diseases. He instituted comprehensive biomarker and mechanism-of-action frameworks linking preclinical discovery to early-human endpoints and partnered closely with Regulatory, Business Development, and Finance to support first-in-human studies and pipeline expansion. His scientific leadership was pivotal during Roche’s due diligence efforts, shaping Poseida’s translational differentiation and value narrative in the evolving gene therapy landscape.
As Vice President and Head of Translational Medicine at Enveda Biosciences, Pavan architected an integrated multi-omics translational platform across inflammatory and fibrotic diseases. He built and scaled high-performing biomarker and MoA teams, embedding AI-enabled decision frameworks into IND-enabling packages aligned with regulatory strategy. His approach combined data science, systems biology, and clinical insight to de-risk development pathways and accelerate precision-medicine therapeutics derived from natural products. Partnering closely with the C-suite, he influenced portfolio prioritization and investor narratives that supported growth-stage financing and corporate expansion.
In 2026, Pavan founded Soha Core Consulting, a strategic biopharma advisory firm based in San Diego. Through this platform, he advises C-suite executives and Boards on translational, clinical, and regulatory strategy across genetic medicines and cardiometabolic disease. He architects biomarker-driven, end-to-end development strategies designed to accelerate IND readiness, enable early proof-of-concept, and mitigate regulatory risk. Serving as both strategic advisor and hands-on operator, he aligns discovery, nonclinical, CMC, and early clinical execution with critical value inflection points. His counsel extends to asset in-licensing, M&A diligence, and pre-IPO positioning, shaping compelling scientific narratives that resonate with regulators, investors, and partners alike.
A recognized thought leader, Pavan has authored more than 100 peer-reviewed publications in leading journals including the New England Journal of Medicine, Nature Communications, Circulation, and Science Translational Medicine. He has contributed book chapters on autophagy and diabetic cardiomyopathy and is a frequent invited speaker at ASGCT, ADA, AHA, Keystone Symposia, and the World Gene Therapy Congress. His academic depth, combined with operational and financial fluency, positions him uniquely as a translational architect capable of shaping both science and enterprise.
Across every chapter of his career, Pavan has demonstrated a consistent pattern: build high-performance teams, design biomarker-informed strategies, navigate regulatory complexity, and convert scientific possibility into clinical and shareholder value. Whether guiding a startup through IPO readiness, resolving an FDA clinical hold, or integrating AI into translational decision-making, he operates with intellectual humility, disciplined execution, and a relentless focus on patient impact. His leadership philosophy emphasizes rigor, accountability, and cross-functional partnership—ensuring that innovation is not only groundbreaking, but also deliverable.
In an era where precision medicine and AI-enabled development are redefining the therapeutic landscape, Pavan Battiprolu represents a new generation of clinician-executive—one who understands that durable enterprise value is built on scientific credibility, strategic clarity, and unwavering commitment to patients. His career is a testament to the power of translational leadership done right: science aligned with strategy, and innovation anchored in purpose.
Character: Pavan exemplifies integrity and intellectual humility, consistently placing patient impact and scientific truth at the center of decision-making. He fosters cultures of accountability and rigor, mentoring leaders to navigate uncertainty with confidence and ethical clarity.
Knowledge: With deep expertise spanning cardiometabolic biology, gene therapy, immunology, and multi-omics platforms, he integrates mechanistic science with regulatory and clinical strategy. His publication record and invited lectures reflect both academic authority and applied translational mastery.
Strategic: Pavan aligns discovery through early clinical execution with clearly defined value inflection points, shaping pipelines that withstand regulatory and market scrutiny. He combines biomarker-driven precision with financial and portfolio insight to build sustainable enterprise growth.
Communication: Equally fluent in scientific detail and board-level narrative, he translates complex biology into compelling value stories for regulators, investors, and partners. His ability to unify cross-functional teams around a shared strategic vision has been central to repeated funding success and organizational scale-up.
